Evidence map›Paper›PMID 30059977›Full record

ArticleInternational journal of epidemiology2019

Mendelian Randomization and mediation analysis of leukocyte telomere length and risk of lung and head and neck cancers.

Linda Kachuri, Olli Saarela, Stig Egil Bojesen, George Davey Smith, Geoffrey Liu, Maria Teresa Landi, Neil E Caporaso, David C Christiani, Mattias Johansson, Salvatore Panico and 60 more

Open access · bronzeAbstract read
In one paragraph

Article in International journal of epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

70 authors at 20 institutions in 18 countries.

Linda KachuriLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Olli SaarelaDivision of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Stig Egil BojesenDepartment of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev Ringvej 75, Herlev, Denmark.
George Davey SmithPopulation Health Science, Bristol Medical School, MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
Geoffrey LiuDivision of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Maria Teresa LandiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Neil E CaporasoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
David C ChristianiDepartments of Epidemiology and Environmental Health, Harvard TH Chan School of Public Health, Boston, MA, USA.
Mattias JohanssonInternational Agency for Research on Cancer, Lyon, France.
Salvatore PanicoDipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
Kim OvervadDepartment of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark.
Antonia TrichopoulouHellenic Health Foundation, and WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Athens, Greece.
Paolo VineisMRC/PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Ghislaine SceloInternational Agency for Research on Cancer, Lyon, France.
David ZaridzeDepartment of Epidemiology and Prevention, Russian N.N.Blokhin Cancer Research Centre, Moscow, Russian Federation.
Xifeng WuDepartment of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Brenda DiergaardeDepartment of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Pagona LagiouDepartment of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Gary J MacfarlaneThe Institute of Applied Health Sciences, School of Medicine, University of Aberdeen, Aberdeen, UK.
Melinda C AldrichDepartment of Thoracic Surgery and Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Adonina TardónFaculty of Medicine, University of Oviedo and CIBERESP, Campus del Cristo, Oviedo, Spain.
Gad RennertClalit National Cancer Control Center at Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.
Andrew F OlshanDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mark C WeisslerDepartment of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Chu ChenFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gary E GoodmanFred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jennifer A DohertyDepartment of Population Health Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Andrew R NessSchool of Oral and Dental Sciences, University of Bristol, Bristol, UK.
Heike BickeböllerDepartment of Genetic Epidemiology, University Medical Center, Georg-August-University, Göttingen, Germany.
H-Erich WichmannInstitute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Angela RischDivision of Epigenomics & Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany.
John K FieldRoy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
M Dawn TeareSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Lambertus A KiemeneyRadboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Erik H F M van der HeijdenRadboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
June C CarrollLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Aage HaugenThe National Institute of Occupational Health, Oslo, Norway.
Shanbeh ZienolddinyThe National Institute of Occupational Health, Oslo, Norway.
Vidar SkaugThe National Institute of Occupational Health, Oslo, Norway.
Victor Wünsch-FilhoFaculdade de Saúde Pública, Universidade de São Paulo, Brazil.
Eloiza H TajaraDepartment of Molecular Biology, School of Medicine of São José do Rio Preto, São José do Rio Preto, Brazil.
Raquel Ayoub MoysésHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Disciplina de Cirurgia de Cabeça e Pescoço (LIM28), São Paulo, Brasil.
Fabio Daumas NunesDepartment of Oral Pathology, School of Dentistry, University of São Paulo, São Paulo, Brazil.
Stephen LamBC Cancer Agency, Vancouver, BC, Canada.
Jose Eluf-NetoDepartamento de Medicina Preventiva, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Martin LackoDepartment of Otorhinolaryngology, Head and Neck Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
Wilbert H M PetersDepartment of Gastroenterology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Loïc Le MarchandEpidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Eric J DuellUnit of Nutrition and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
Angeline S AndrewDepartment of Epidemiology, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Silvia FranceschiInternational Agency for Research on Cancer, Lyon, France.
Matthew B SchabathDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Jonas ManjerSkåne University Hospital, Lund University, Lund, Sweden.
Susanne ArnoldMarkey Cancer Center, University of Kentucky, Lexington, KY, USA.
Philip LazarusCollege of Pharmacy, Washington State University, Spokane, WA, USA.
Anush MukeriyaDepartment of Epidemiology and Prevention, Russian N.N.Blokhin Cancer Research Centre, Moscow, Russian Federation.
Beata SwiatkowskaDepartment of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland.
Vladimir JanoutFaculty of Health Sciences, Palacky University, Olomouc, Czech Republic.
Ivana HolcatovaInstitute of Public Health and Preventive Medicine, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
Jelena StojsicDepartment of Thoracopulmonary Pathology, Service of Pathology, Clinical Center of Serbia, Belgrade, Serbia.
Dana MatesNational Institute of Public Health, Bucharest, Romania.
Jolanta LissowskaDepartment of Cancer Epidemiology and Prevention, Cancer Center Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland.
Stefania BocciaFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italia.
Corina LesseurInternational Agency for Research on Cancer, Lyon, France.
Xuchen ZongLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
James D McKayInternational Agency for Research on Cancer, Lyon, France.
Paul BrennanInternational Agency for Research on Cancer, Lyon, France.
Christopher I AmosInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
Rayjean J HungLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Centre international de recherche sur le cancer · FRNational Institute of Occupational Health · NONational Institutes of Health · USRadboud University Nijmegen · NLUniversity of Toronto · CAFred Hutch Cancer Center · USHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRLunenfeld-Tanenbaum Research Institute · CANational and Kapodistrian University of Athens · GRRussian Cancer Research Center NN Blokhin · RUUniversidade de São Paulo · BRUniversity of North Carolina at Chapel Hill · USAarhus University · DKBaylor College of Medicine · USBC Cancer Agency · CACarmel Medical Center · ILCentar za Promociju Nauke · RSCharles University · CZDartmouth College · USFaculdade de Medicina de São José do Rio Preto · BR

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 2004 to 2026
$49.6M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI KATHLEEN L. O'CONNOR · 2013 to 2026
$38.3M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3M
Translating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos · 2017 to 2026
$23.7M
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) StudyZIACP010195 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBANES, DEMETRIUS · 2009 to 2025
$22.5M
THE ROLE OF CAL IN CIF-MEDIATED DEGRADATION OF CFTRP20RR018787 · NCRR · DARTMOUTH COLLEGE · PI GRISWOLD, KARL E · 2003 to 2011
$21.9M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
THE CAROTENE AND RETINOL EFFICACY TRIAL (CARET)U01CA063673 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 1994 to 2006
$13.0M
SPORE in Lung CancerP50CA119997 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GABRILOVICH, DMITRY I · 2008 to 2012
$11.0M
Cancer Research UK 19169Cancer Research UK C18281/A19169Department of Health RP-PG-0707-10034Medical Research Council G0902313Medical Research Council MC_UU_00011/1Medical Research Council MR/L01341X/1NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1 TR000445NCI NIH HHS K07 CA172294NCI NIH HHS P30 CA047904NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA177558NCI NIH HHS P50 CA097190NCI NIH HHS P50 CA119997NCI NIH HHS R01 CA074386NCI NIH HHS R01 CA090731NCI NIH HHS R01 CA092039NCI NIH HHS R01 CA111703NCI NIH HHS R01 CA151989NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA063673NCI NIH HHS U01 CA167462NCI NIH HHS U19 CA148127NCI NIH HHS U19 CA203654NCI NIH HHS UM1 CA167462NCRR NIH HHS P20 RR018787NIDCR NIH HHS R01 DE013158NIEHS NIH HHS P30 ES010126World Health Organization 001
6 · The paper itself

Abstract

backgroundEvidence from observational studies of telomere length (TL) has been conflicting regarding its direction of association with cancer risk. We investigated the causal relevance of TL for lung and head and neck cancers using Mendelian Randomization (MR) and mediation analyses.

methodsWe developed a novel genetic instrument for TL in chromosome 5p15.33, using variants identified through deep-sequencing, that were genotyped in 2051 cancer-free subjects. Next, we conducted an MR analysis of lung (16 396 cases, 13 013 controls) and head and neck cancer (4415 cases, 5013 controls) using eight genetic instruments for TL. Lastly, the 5p15.33 instrument and distinct 5p15.33 lung cancer risk loci were evaluated using two-sample mediation analysis, to quantify their direct and indirect, telomere-mediated, effects.

resultsThe multi-allelic 5p15.33 instrument explained 1.49-2.00% of TL variation in our data (p = 2.6 × 10-9). The MR analysis estimated that a 1000 base-pair increase in TL increases risk of lung cancer [odds ratio (OR) = 1.41, 95% confidence interval (CI): 1.20-1.65] and lung adenocarcinoma (OR = 1.92, 95% CI: 1.51-2.22), but not squamous lung carcinoma (OR = 1.04, 95% CI: 0.83-1.29) or head and neck cancers (OR = 0.90, 95% CI: 0.70-1.05). Mediation analysis of the 5p15.33 instrument indicated an absence of direct effects on lung cancer risk (OR = 1.00, 95% CI: 0.95-1.04). Analysis of distinct 5p15.33 susceptibility variants estimated that TL mediates up to 40% of the observed associations with lung cancer risk.

conclusionsOur findings support a causal role for long telomeres in lung cancer aetiology, particularly for adenocarcinoma, and demonstrate that telomere maintenance partially mediates the lung cancer susceptibility conferred by 5p15.33 loci.

Indexed as

Adenocarcinoma of LungAgedAged, 80 and overCarcinoma, Squamous CellChromosomes, Human, Pair 5FemaleHead and Neck NeoplasmsHumansLeukocytesLung NeoplasmsMaleMendelian Randomization AnalysisMiddle AgedSquamous Cell Carcinoma of Head and NeckTelomereTelomere Homeostasischromosome 5p15.33lung cancermediation analysisMendelian Randomizationtelomere lengthTERT

Identifiers

PMID30059977
PMCPMC6659464
OpenAlexW2891462488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.